We are not listening to any predictions from LC about “how long it will take.” As you recall, you advised us that “no peer review is coming” and your prediction was followed by the peer-review published by JAMA along with two other notable peer-reviewed papers relevant to DCVax-L.
I think that any prediction or advice from LC is likely to be a “FLOPPER.”
“No peer review” vs. THREE independently peer-reviewed publications is a very big difference. Those papers are invaluable to a pre-commercial biotech.
Along with regulatory developments, these are the indicators specific to NWBO that are the most determinative:
⭐️Combos ⭐️Licensing Deals ⭐️EDEN
Relevant features of the three indicators above with regard to NWBO:
We may not know whether Merck or BMS or any other company is interested in NWBO, but we do know that BP companies follow clinical trials and they read the peer-reviewed medical literature—they reference and cite clinical data and peer review all the time. We don’t have insider information, but we do have publicly available facts to consider with regard to the overall PD-1 market and all of the BP companies that have or are developing PD-1 drugs.
DC technologies owned by NWBO are being investigated in combo with several BP products at UCLA and at Roswell, including Merck’s pembrolizumab.
Relatively recently, Merck hired an expert in dendritic cell technology (Dr. Butterfield).
Combining PD-1 blockade with dendritic cell vaccines is a relatively new idea. The combo trials at UCLA and Roswell have reached PII, and data are beginning to emerge. PD-1 technology has only been commercially available for 10 years and the drug class is growing along with its demand globally.
Research the rapidly expanding worldwide immunotherapy market and the significance of emerging data about combo agents that have the potential to enhance or unlock the efficacy of PD-1 blockade technology.
Market Data 
Markets 
AI
